Molly Elisabeth Dela Cruz, MD General Practice Medicare: Medicare Enrolled Practice Location: 18511 Highlander Medics St, Fort Bliss, TX 79906 Phone: 915-742-9439 |
Dr. Kristen Garvie, MD General Practice Medicare: Medicare Enrolled Practice Location: 18511 Highlander Medics St, Fort Bliss, TX 79906 Phone: 915-742-7777 |
Matthew Mcclenathan, General Practice Medicare: Not Enrolled in Medicare Practice Location: 18511 Highlander Medics St, Fort Bliss, TX 79906 Phone: 915-742-7777 |
Sterling Mckissack, M.D. General Practice Medicare: Accepting Medicare Assignments Practice Location: 18511 Highlander Medics St, Fort Bliss, TX 79906 Phone: 915-742-9273 |
Marco Jose Dela Cruz, MD General Practice Medicare: Medicare Enrolled Practice Location: 18511 Highlander Medics St, Fort Bliss, TX 79906 Phone: 608-630-1582 |
Parker Lovelace, DO General Practice Medicare: Medicare Enrolled Practice Location: 18511 Highlander Medics St, Fort Bliss, TX 79906 Phone: 210-228-6416 |
Shamim Samandar Nafea, DO, MPH General Practice Medicare: Not Enrolled in Medicare Practice Location: 18511 Highlander Medics St, Fort Bliss, TX 79906 Phone: 707-326-0049 |
News Archive
Karo Bio AB (publ) has decided to discontinue the development program for eprotirome after an animal study has demonstrated unwanted effects following long-term exposure. The planned spin-off of the preclinical part of operations will not proceed.
CASI Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, announced today that its orally-active, Aurora A/angiogenic kinase inhibitor, ENMD-2076, has received Orphan Drug designation from the U.S. Food and Drug Administration for the treatment of hepatocellular carcinoma (HCC).
The Affordable Care Act was signed into law March 23, 2010, with the aim of extending medical coverage to more Americans. The law has been a political football, and arguments continue to rage over whether it's good or bad for the country. This, however, is simply the story of how it affected one person.
A team of researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with GenScript, is developing a synthetic antibody to SARS-CoV-2, the virus that causes coronavirus disease (COVID-19). This antibody is intended to block the virus from entering human lung cells, and would be another potential treatment option for COVID-19.
Staphylococcus aureus - better known as Staph - is a common inhabitant of the human nose, and people who carry it are at increased risk for dangerous Staph infections.
› Verified 9 days ago